Victor Lundin is a dedicated scientist at Genentech, where he plays a pivotal role as the analytical lead for the pre-clinical, clinical, and commercial development of innovative protein therapeutics. His expertise encompasses a range of advanced biopharmaceuticals, including antibody-drug conjugates and bispecific antibodies, which are...
Victor Lundin is a dedicated scientist at Genentech, where he plays a pivotal role as the analytical lead for the pre-clinical, clinical, and commercial development of innovative protein therapeutics. His expertise encompasses a range of advanced biopharmaceuticals, including antibody-drug conjugates and bispecific antibodies, which are at the forefront of targeted therapies in oncology and other therapeutic areas. Victor's passion for bridging chemistry and biology is evident in his comprehensive approach to assay development and physicochemical characterization, where he identifies critical quality attributes essential for ensuring the safety and efficacy of therapeutic candidates.
In his current role, Victor excels in managing interdisciplinary collaborations within matrixed teams, fostering an environment where innovative ideas can flourish while effectively managing project timelines and mitigating risks. His deep understanding of drug development processes is complemented by his proficiency in high-performance liquid chromatography (HPLC), which he utilizes to achieve precise analytical results that inform control strategies and regulatory filings. Victor's contributions extend beyond laboratory work; he is also skilled in scientific writing and grant preparation, ensuring that his team's findings are communicated clearly and effectively to stakeholders.
Victor's commitment to advancing the field of protein engineering is matched by his dedication to mentorship and education, as he actively engages in university teaching and supports the next generation of scientists. Through his multifaceted expertise and collaborative spirit, Victor Lundin continues to drive innovation at Genentech, contributing to the development of groundbreaking therapies that have the potential to transform patient care.
